Novo Nordisk – Growth Continues At Pace
Excluding the impact of currency changes, Novo Nordisk A/S (NYSE:NVO)’s sales during the first nine months of the year rose 13% to 102.5bn Danish Kroner (DKK). This was driven by strong growth in GLP-1 treatments while Biopharm sales saw a modest uptick. Q3 2021 hedge fund letters, conferences and more Operating profit for the period rose 12% to DKK 45bn. The group announced plans to expand its buyback programme by DKK 2bn to DKK 20bn and expects underlying full year sales and operating profit growth between 12% and 15% The shares rose 1.6% following the announcement Novo Nordisk GLP-1 SalesLa...